1 / 25

STERICYCLE (SRCL)

STERICYCLE (SRCL). Ross Pevitz Matt Storkman Shengdong Zhu RCMP Presentation April 10, 2007. Position. May, 2001 Bought 200 Shares Purchase for $19.47 ($3,894) Current Price is $81.92 ($16,384) $12,490 Unrealized Gain 5% of Portfolio. History. 1989- Stericycle founded

nicholasmills
Download Presentation

STERICYCLE (SRCL)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. STERICYCLE(SRCL) Ross Pevitz Matt Storkman Shengdong Zhu RCMP Presentation April 10, 2007

  2. Position • May, 2001 Bought 200 Shares • Purchase for $19.47 ($3,894) • Current Price is $81.92 ($16,384) • $12,490 Unrealized Gain • 5% of Portfolio

  3. History • 1989- Stericycle founded • Medical Waste Tracking Act • Strict regulations for dealing with Medical Waste • Afford convenient, cost effective, and efficient solutions • 1993- Acquired over 116 companies since 1993 • 1996- IPO • 2000- North America’s Largest Provider of regulated Medical Waste Management Services

  4. Company Background • Headquarters in Lake Forest, IL • Largest and Only Full-Service Provider • 351,700 Accounts • Growing Presence Internationally • Major operations UK, Ireland, Mexico, Canada, Brazil, Argentina, South Africa, Australia, and Japan

  5. Products and Services • Mission: Help healthcare organizations reduce risk, provide a safer workplace, and stay in compliance with national, state, and local regulations. • Offer collection, transportation, treatment, disposal, and recycling of medical waste • Treatment: Incineration (burn), Proprietary Autoclaving (steam) ^Proprietary ETD, Electro-Thermal Deactivation (grinding) • Stericycle • Medical Waste Services • Bio-systems • **Sharps Management • Water Management Service • RX Waste Compliance Program • **Pharmaceutical Services

  6. Products and Services • Offer training, educational, consulting, and documentation services • (Steri-Safe) • OSHA and HIPPA Compliance– Occupational Safety and Health Administration, Health Insurance Portability and Accountability Act • Product Sales

  7. Industry Supply • Fragmented • Local Providers, Onsite Treatment, Alt. Treatment • Competitive • Drive Cost, Quality, and Geographic location • Highly Regulated • EPA, DEA, FDA, OSHA, DOT, State/Local • Insulated from Economic Cycles • LT contracts, Nature of Industry • Large Account Customers vs Small Account Customers

  8. Industry Demand • Pressure to Reduce Healthcare Costs • Aging Population • Baby Boomers • Better Health Care • Stricter Environmental and Safety Regulations • Larger Fines and Unaware market

  9. Economic Risks • Interest Rate, Inflation, GDP, Competition • Energy Costs • Transportation and Treatment • Foreign Exchange Risk • Changing Government Regulations!!! • Patent and Trademark Expiration • Liabilities and Insurance • Clean up costs, personal injury, ect.

  10. Competitive Advantages • Established Brand Name and Market Leader • Strong Management Team • Low Cost Operator • Economies of Scale • Full Service Provider • Vertically Integrated, growing Horizontally • Loyal and Diverse Customers • Revenue retention >95% • Largest customers <2% of Revenues • LT contracts with automatic renewal and price ↑ provisions

  11. Company Growth • Shift From Large to Small Customers • Bigger Gross Margins • 55-60% small vs 15-30% large • Expand Range of Services and Products (Organic) • Expand Bio-Systems • Since acquisition of Scherer Healthcare, Inc. in January 2003 • Grow Pharmaceutical Services • Proprietary data system to remove expired or unsafe products

  12. Company Growth • Continue Acquisitions • Focus on strategic “tuck in” • Proven Integrator ~ 116 acquisitions since 1993 • Mainly Asset Purchases • Price determined by multiples of EBITDA and quality of asset Revenues

  13. Company Growth • Increasing Margins • Sell Premium Steri-Safe Service • Customer Size • Acquisitions- lagged • Slightly Offset • Bio-systems • Int’l Emergence EBIT CAGR- Compound Annual Growth Rate Margins

  14. Company Growth • Global Markets • Expand Technology Licensing • Australia, Brazil, Japan and South Africa • Acquire Lead Position • Canada and UK • JV or Partnership • Mexico and Argentina • Small Initial Outlay • Very Selective in Process

  15. Cash Flow Valuation Model • Revenue growth projected to continue, through both organic growth and steady acquisitions • Assets for sale amount booked in 2006 is expected to be liquidated in 2007 for cash inflow (net $26.5M) • Continuing trend of acquisitions, though with lower margins • Acquisitions have been paying off as margins have held steady and have even increased from 1999

  16. Discounted Cash Flow • WACC calculated to be 6.93% • This figure was based on the highest beta estimate of 0.4 (provided by Bloomberg) • Other agencies have estimated negative and zero Beta • Cap structure is 86% equity (market value) • Cost of Equity: 7.44% Cost of Debt:6.10% • Margins projected to decrease from 2004/2006 levels

  17. DCF • Selling, General and Administrative expenses are forecast to increase from 18% to 20% of sales due to increased requirements of management for maintaining company infrastructure • Discounted Cash Flow valuation yields a range of value from $81 – $99 • DuPont Analysis reveals coherent assumptions and slowly decreasing margins

  18. Sensitivity Analysis on WACC and Terminal Growth Rate A range from $70.51 to $103.81

  19. Competitors • Who? • American Ecology Corp (ECOL) • Microtek Medical Holdings Inc. (MTMD) • Waste Management, Inc (WMI) • Waste Management Industry • Why? • Industry specific • Strong/Solid performers • Multiples in line with Industry

  20. Critical Multiples Comparison • Gross Margin • Operating Margins • Enterprise Value/Revenue • Enterprise Value/EBITDA • EPS

  21. Performance Vs. Competitors

  22. Stericycle Comparable Companies Valuation • P/E: $50.19 • Enterprise Value/EBITDA $42.00 • Enterprise Value/Revenue $30.64 • Comps Valuation Price $40.94

  23. Portfolio Analysis • Small Correlation with Market • Good Diversification with Portfolio

  24. Valuation Discussion: Hold • The low estimate of the discounted cash flow valuation represents the current market price of SRCL • $81 is also the year-high for the stock • Comparable company valuation places a much lower value on the stock • SRCL is trading at a large premium compared to its peers • SRCL outperforms all of its peers in operating metrics such as gross margin and operating margin • DCF analysis and forecasting provide reasoning and reinforce the market’s premium for SRCL • Analyst Team recommends holding SRCL

  25. Questions? • Love to Entertain!!!

More Related